Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.

Name: Αlpha¹ Rigor Record — Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Item: Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Rating: 59
Author: Αlpha¹

Karst M, Meissner W, Sator S, Keßler J, Schoder V, Häuser W

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 2 high issues for “Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
StatisticsPrinted percentage does not match its own count (capped) ×2−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 36 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced5 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 3 randomized controlled trial of a cannabis extract for chronic low back pain. The methods are rigorous, with clear randomization, blinding, sample size justification, and comprehensive reporting of demographics, ethics, and data availability. Minor reporting inconsistencies and copyedit issues exist but do not undermine the overall integrity.

Both reviewers classified the study as interventional and agreed on all dimensions. The statistics verification component recomputed only a subset of tests (5 total, 3 consistent, 2 inconsistent with no decision errors); this does not constitute a full validation of all statistical results. The citation check found no retracted or non-existent references. The integrity check flagged two low-severity internal contradictions (enrollment vs. analysis population, and a p-value discrepancy) that are addressed in the action items.

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks. 2 printed percentages that do not match their own count.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior work on the prevalence and burden of CLBP, the risks of NSAIDs and opioids, and the limitations of existing cannabis-based medicine studies (small samples, short durations, inconsistent dosing). It explicitly states that the study addresses a critical gap by providing a large-scale, placebo-controlled phase 3 trial with a chemically well-defined extract. The rationale linking the premise to the study objectives is logical and well-supported.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on the limitations of current CLBP treatments and the need for cannabis-based alternatives, and it addresses gaps in prior cannabis research.

Evidence

paraphrase[Introduction, paragraphs 1-3]

“The limitations of existing treatments and the stagnation in the development of new analgesics have fueled growing public and scientific interest in the use of cannabis-based medicines for the management of chronic pain. However, the quality of evidence supporting the clinical use of cannabis-based products remains low, primarily due to small sample sizes, short treatment durations, inconsistent dosing regimens, heterogeneous outcome measures and variability across cannabis-based preparations.”

direct quote[Introduction, last paragraph]

“By providing a large-scale, placebo-controlled phase 3 trial of adequate duration using a chemically well-defined, full-spectrum cannabis extract in CLBP, this study addresses a critical gap in the clinical research of cannabis-based pharmacotherapy in chronic pain.”